Log in

Relevant bibliographies by topics / Cardiac Resynchronization Therapy Devices / Journal articles

To see the other types of publications on this topic, follow the link: Cardiac Resynchronization Therapy Devices.

Journal articles on the topic 'Cardiac Resynchronization Therapy Devices'

Author: Grafiati

Published: 4 June 2021

Last updated: 26 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Cardiac Resynchronization Therapy Devices.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Chapa, Deborah W., Hyeon-Joo Lee, Chi-Wen Kao, Erika Friedmann, Sue A. Thomas, Jill Anderson, and Gust H. Bardy. "Reducing Mortality With Device Therapy in Heart Failure Patients Without Ventricular Arrhythmias." American Journal of Critical Care 17, no. 5 (September 1, 2008): 443–52. http://dx.doi.org/10.4037/ajcc2008.17.5.443.

Full text

Abstract:

Use of device therapy to prevent sudden cardiac death in patients with heart failure is expanding on the basis of evidence from recent clinical trials. Three multicenter prospective clinical trials—Sudden Cardiac Death in Heart Failure (SCD-HeFT); Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION); and Cardiac Resynchronization-Heart Failure (CARE-HF)—were conducted to determine the effectiveness of devices in reducing mortality in patients with heart failure who did not have a history of ventricular arrhythmias. The 3 trials varied in the devices used, the population of patients included, and the study designs. In SCD-HeFT, implantable cardioverter defibrillators were more effective than pharmacological therapy in preventing mortality among patients with mild to moderate heart failure. In COMPANION, cardiac resynchronization therapy alone and cardiac resynchronization therapy plus an implantable cardioverter defibrillator were more effective than optimal drug treatment in reducing morbidity and all-cause mortality in patients with moderate to severe heart failure. In CARE-HF, cardiac resynchronization therapy alone was more effective than optimal drug treatment in reducing all-cause mortality in patients with moderate to severe heart failure. No direct comparison of the devices used has been done. These 3 clinical trials provide clear evidence that device therapy is beneficial for some patients with heart failure, even patients who do not have a history of ventricular arrhythmia.

APA, Harvard, Vancouver, ISO, and other styles

2

Bitakova, Fatima I., Victoria E. Gumerova, Elizaveta V. Zbyshevskaya, Vera Y. Zimina, Tatiana N. Novikova, Rodion V. Ratmanov, Sergey A. Saiganov, and Vladislava A. Shcherbakova. "Nuances of Cardiac Resynchronization Therapy in Patients with Dilated Cardiomyopathy and Atrial Fibrillation (a Clinical Case)." Cardiac Arrhythmias 1, no. 1 (June 15, 2021): 33–38. http://dx.doi.org/10.17816/cardar75647.

Full text

Abstract:

Dilated cardiomyopathy (DCM) is a steadily developing disease characterized by progressive chronic heart failure (CHF) resistant to drug therapy. Cardiac resynchronization therapy (CRT) significantly improves the prognosis in these patients if they have indications for implantation of resynchronization devices. The article presents a clinical case of successful implantation of a cardioversion-defibrillation cardiac resynchronization device in a patient suffering from DCM in combination with permanent atrial fibrillation (AF). The nuances of ventricular rate control and the role of the catheter procedure for modifying the atrioventricular junction are discussed.

APA, Harvard, Vancouver, ISO, and other styles

3

Bangaar, Dr Ashish. "Octogenarian with Severe Left Ventricular Dysfunction and Cardiac Resynchronization TherapyDefibrillator Device: Successful Anesthesia Management for Hip Arthroplasty." Corpus Journal of Case Reports (CJCR) 3, no. 3 (July 29, 2022): 1–3. http://dx.doi.org/10.54026/cjcr/1024.

Full text

Abstract:

Cardiac resynchronization therapy has emerged as a key component in management of advanced heart failure with reduced ejection fraction in selected subset of geriatric patients. The burgeoning burden of comorbidities, complexity of these devices and aging population presenting for surgeries necessitates peri-operative physicians to be cognizant and confident to handle these challenging cases. Limited literature about anesthesia management of patients implanted with these devices add to the situational challenge. We present a case of elderly gentleman with ischemic cardiomyopathy and cardiac resynchronization therapy-defibrillator device who underwent hip replacement under general anesthesia. Understanding the disease and the device are the crucial and definitive exigencies to manage such cases.

APA, Harvard, Vancouver, ISO, and other styles

4

Gardini, Armando, Pierpaolo Lupo, Emanuela Zanelli, Silvia Bisetti, and Riccardo Cappato. "Diagnostic capabilities of devices for cardiac resynchronization therapy." Journal of Cardiovascular Medicine 11, no. 3 (March 2010): 186–89. http://dx.doi.org/10.2459/jcm.0b013e3283303036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Krishnan, Subramaniam C., Laurens F. Tops, and Jeroen J. Bax. "Cardiac Resynchronization Therapy Devices Guided by Imaging Technology." JACC: Cardiovascular Imaging 2, no. 2 (February 2009): 226–30. http://dx.doi.org/10.1016/j.jcmg.2008.11.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Yang, Ying chi, Thein Tun Aung, and Abdul Wase. "Inappropriate Defibrillator Shocks due to Mechanical Inference from an Investigational Device." Case Reports in Cardiology 2019 (January 6, 2019): 1–3. http://dx.doi.org/10.1155/2019/2810396.

Full text

Abstract:

Cardiac contractility modulation (CCM) is an investigational device-based therapy to enhance ventricular contractility in systolic heart failure patients who are not candidates for cardiac resynchronization therapy (CRT) owing to the absence of wide QRS complexes or who have failed to respond on CRT. The principal mechanism is based on the stimulation of cardiac muscles by nonexcitatory electrical signals to augment the influx of calcium ions into the cardiomyocytes. The majority of patients receiving CCM therapy have concurrent implantable cardioverter defibrillators, and the manufacturer declares both devices can be used in parallel without any interactions. Nevertheless, proper lead positioning of both devices are crucial, and it is mandatory to check device-device interactions during each and every cardiac electronic implantable device-related procedure to prevent adverse outcomes.

APA, Harvard, Vancouver, ISO, and other styles

7

Malik, Jahanzeb, and Kashif Khan. "Cardiac implantable electronic device related chest pain: A focused review." Journal of Shifa Tameer-e-Millat University 4, no. 1 (August 1, 2021): 50–54. http://dx.doi.org/10.32593/jstmu/vol4.iss1.130.

Full text

Abstract:

More than 600,000 patients undergo cardiac implantable electronic device (CIED) implantation in a year, which comprise of pacemakers, implantable cardioverter defibrillators, and cardiac resynchronization therapy devices (CRT). The most common symptom experienced after a CIED implantation is chest pain. In this review, we describe CIED implantation and associated complications causing chest pain.

APA, Harvard, Vancouver, ISO, and other styles

8

Imamura, Teruhiko. "Ischemic Etiology and Clinical Outcomes Following Cardiac Resynchronization Therapy." Medicina 56, no. 3 (March 4, 2020): 110. http://dx.doi.org/10.3390/medicina56030110.

Full text

Abstract:

Optimal patient selection for cardiac resynchronization therapy is crucial. There are several concerns that allow to better clarify the association between the ischemic etiology of heart failure and the response to cardiac resynchronization therapy. The type of ischemic coronary disease has an impact on the responses to cardiac resynchronization therapy. The prognostic impact of cardiac resynchronization therapy on cardiac death including heart transplantation and durable ventricular assist device implantation is another concern.

APA, Harvard, Vancouver, ISO, and other styles

9

Bontempi, Luca, Francesca Vassanelli, and Antonio Curnis. "Resynchronization Therapy in the Elderly." European Journal of Arrhythmia & Electrophysiology 02, no. 01 (2016): 18. http://dx.doi.org/10.17925/ejae.2016.02.01.18.

Full text

Abstract:

Implantable cardioverter-defibrillators (ICDs) are increasingly used in patients ≥80 years old, and the proportion of devices incorporating cardiac resynchronization therapy (CRT) increases with patient age. In this era of patient-centered care, important questions arise about the patterns of use, clinical outcomes and cost-effectiveness of CRT for older patients. Currently, few data are available that specifically address the effects of CRT in the elderly.

APA, Harvard, Vancouver, ISO, and other styles

10

Świerżyńska, Ewa, and Maciej Sterliński. "Decreases in biventricular pacing percentage in remote monitoring of patients with cardiac implantable electronic devices." In a good rythm 1, no. 62 (May 31, 2022): 17–20. http://dx.doi.org/10.5604/01.3001.0015.9157.

Full text

Abstract:

Heart failure is a serious disease and is one of the top causes of death in Poland. A proven method of treatment in some heart failure patients is resynchronization therapy using implantable devices such as cardioverter-defibrillators (CRT-D) or pacemakers (CRT-P). One of the conditions for the effectiveness of this therapy is achieving and maintaining a high biventricular pacing percentage. Remote monitoring of cardiac implantable electronic devices allows daily access to information about a device’s operating status. In patients with heart failure, access and treatment options based on remote monitoring data reduces hospitalization, mortality and treatment costs. This article discusses how information received via remote monitoring about the loss of resynchronization stimulation can be used to determine possible abnormalities and the need for treatment.

APA, Harvard, Vancouver, ISO, and other styles

11

Imnadze, Guram, Khaled Awad, Wolfgang Kranig, and Irakli Giorgberidze. "Modified Pull-Through Technique for Cardiac Resynchronization Therapy Upgrades in Patients with Occluded Access Veins." Texas Heart Institute Journal 47, no. 1 (February 1, 2020): 23–26. http://dx.doi.org/10.14503/thij-18-6713.

Full text

Abstract:

The number of procedures for upgrading implantable devices for cardiac resynchronization therapy has increased considerably during the last decade. A major challenge that operators face in these circumstances is occlusion of the access vein. We have modified a pull-through method to overcome this obstacle. Six consecutive patients with occluded access veins and well-developed collateral networks underwent a procedure in which the occluded vein was recanalized by snaring the existing atrial lead via transfemoral access. Upgrading the device was successful in all patients; none had intraprocedural complications. Our experience shows that our modified pull-through technique may be a feasible alternative for upgrading cardiac resynchronization therapy in patients with venous occlusion.

APA, Harvard, Vancouver, ISO, and other styles

12

Świerżyńska, Ewa, and Artur Oręziak. "RADIOTHERAPY IN PATIENTS WITH IMPLANTED ELECTRONIC CARDIAC DEVICES IN LIGHT OF THE 2021 ESC CARDIAC PACING AND CARDIAC RESYNCHRONIZATION THERAPY GUIDELINES." In a good rythm 4, no. 61 (January 31, 2022): 8–10. http://dx.doi.org/10.5604/01.3001.0015.8132.

Full text

Abstract:

Radiotherapy is a common treatment modality for cancer. In patients with cancer and implanted cardiac electrotherapy devices, radiotherapy may however interfere with the operation of these devices. In severe cases, this malfunction can lead to irreparable damage to such devices, which requires their replacement. Experience has shown that, with appropriate treatment conditions and safety procedures in place, the risk of radiotherapy causing such disturbances in patients with implantable cardiac devices is low. The rules for managing oncology patients with implantable devices during radiotherapy were included in the latest guidelines published by the European Society of Cardiology concerning cardiac pacing and resynchronization therapy.

APA, Harvard, Vancouver, ISO, and other styles

13

Gierula, John, Maria F. Paton, and Klaus K. Witte. "Advances in cardiac resynchronization and implantable cardioverter/defibrillator therapy: Medtronic Cobalt and Crome." Future Cardiology 17, no. 4 (July 2021): 609–18. http://dx.doi.org/10.2217/fca-2020-0117.

Full text

Abstract:

Cardiovascular implantable electronic devices have revolutionized the management of heart failure with reduced ejection fraction. New device generations tend to be launched every few years, with incremental improvements in performance and safety and with an expectation that these will improve patient management and outcomes while remaining cost-effective. As a result, today’s cardiac resynchronization therapy (CRT) and implantable cardioverter defibrillator devices are quite different from the pioneering but often bulky devices of the late 20th century. This review discusses new and improved features developed to target specific needs in managing heart failure patients, some of which are especially pertinent to the current worldwide healthcare situation, with focus on the latest generation of CRTs with defibrillator (CRT-Ds) and implantable cardioverter defibrillators from Medtronic.

APA, Harvard, Vancouver, ISO, and other styles

14

Moura-Ferreira, Sara, Helena Gonçalves, Marco Oliveira, João Primo, Paulo Fonseca, José Ribeiro, Elisabeth Santos, Nuno Pelicano, Dinis Martins, and Vasco Gama. "A devices’ game of thrones: cardiac resynchronization therapy vs. pacemaker." EP Europace 19, no. 12 (April 18, 2017): 2042–46. http://dx.doi.org/10.1093/europace/eux081.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Samii, Soraya M., and Javier E. Banchs. "Implantable Cardiac Devices in the Treatment of Arrhythmias and Congestive Heart Failure." Spring 9, no. 1 (February 21, 2012): 47–52. http://dx.doi.org/10.15420/usc.2012.9.1.47.

Full text

Abstract:

The concept of using an implantable device to manage arrhythmias and heart failure started over 50 years ago. Since then, we have seen these devices improve patient outcomes from bradyarrhythmias, atrial fibrillation, ventricular arrhythmias, and heart failure. These devices are now standard of care in the management of patients and include pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy (CRT) or combination devices. The future may hold expansion of the indications for these devices, with careful examination of the outcomes of today's patients. In addition, there is very exciting new technology that may further advance the management of arrhythmias and heart failure.

APA, Harvard, Vancouver, ISO, and other styles

16

Samii, Soraya M., and Javier E. Banchs. "Implantable Cardiac Devices in the Treatment of Arrhythmias and Congestive Heart Failure." Winter 9, no. 2 (November 8, 2012): 99–104. http://dx.doi.org/10.15420/usc.2012.9.2.99.

Full text

Abstract:

The concept of using an implantable device to manage arrhythmias and heart failure started over 50 years ago. Since then, we have seen these devices improve patient outcomes from bradyarrhythmias, atrial fibrillation, ventricular arrhythmias, and heart failure. These devices are now standard of care in the management of patients and include pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy (CRT) or combination devices. The future may hold expansion of the indications for these devices, with careful examination of the outcomes of today's patients. In addition, there is very exciting new technology that may further advance the management of arrhythmias and heart failure.

APA, Harvard, Vancouver, ISO, and other styles

17

Shumakov, D. V., D. I. Zybin, M. A. Popov, V. V. Dontsov, and E. G. Agafonov. "Resynchronization therapy in end-stage heart failure." Russian Medical Inquiry 5, no. 4 (2021): 206–11. http://dx.doi.org/10.32364/2587-6821-2021-5-4-206-211.

Full text

Abstract:

Heart failure (HF) is a common condition, and its overall prevalence is constantly growing. HF ultimately progresses to end-stage disease that is refractory to optimal medical therapy and requires implantable devices or heart transplant. In recent years, cardiac resynchronization therapy (CRT) has been generally accepted in patients with NYHA class III or IV, reduced left ventricular ejection fraction (less than 35%), and the wide QRS complex (>120 msec). CRT improves the efficacy of heart ventricle function and, as a result, physical performance and quality of life. Reverse cardiac remodeling occurs at a pathophysiological level that improves systolic function. Patients with end-stage HF who are on the heart transplant list are a specific group in whom CRT is considered a “bridge” to surgery. This review paper discusses state-of-the-art, advances, and unresolved issues in this area. KEYWORDS: cardiac resynchronization therapy, heart failure, left ventricular remodeling, ejection fraction, heart transplant. FOR CITATION: Shumakov D.V., Zybin D.I., Popov M.A. et al. Resynchronization therapy in end-stage heart failure. Russian Medical Inquiry. 2021;5(4):206–211 (in Russ.). DOI: 10.32364/2587-6821-2021-5-4-206-211.

APA, Harvard, Vancouver, ISO, and other styles

18

Riedlbauchová, Lucie, Václav Durdil, Jakub Honěk, and Josef Veselka. "Nonpharmacological Treatment of Atrial Fibrillation: What Is the Role of Device Therapy?" International Journal of Angiology 29, no. 02 (April 28, 2020): 113–22. http://dx.doi.org/10.1055/s-0040-1708529.

Full text

Abstract:

AbstractAtrial fibrillation is the most common arrhythmia in the adult population, and its incidence and prevalence are still rising. Cardiac devices are widely used in clinical practice in the management of various rhythm disturbances and heart failure treatment. Many patients who receive a pacemaker, implantable cardioverter-defibrillator, or cardiac resynchronization therapy also experience atrial fibrillation in the course of their life. Therefore, this review aims to describe the role of these devices in the treatment and prevention of atrial fibrillation in the device recipients. In addition, all these implantable devices also serve as permanent ECG (electrocardiogram) monitors, thus providing important information about the presence and characteristics of atrial fibrillation that may or may not be detected by the patient but can modify our therapeutical approach with regard to the stroke prevention.

APA, Harvard, Vancouver, ISO, and other styles

19

Tumampos, J., N. Wulf, H. Kühnert, O. Solbrig, J. Querengässer, and M. Heinke. "Cardiac index in atrio- and interventricular delay optimized cardiac resynchronization therapy and cardiac contractility modulation." Current Directions in Biomedical Engineering 1, no. 1 (September 1, 2015): 89–91. http://dx.doi.org/10.1515/cdbme-2015-0023.

Full text

Abstract:

AbstractCardiac resynchronization therapy (CRT) is an established therapy for heart failure patients and improves quality of life in patients with sinus rhythm, reduced left ventricular ejection fraction (LVEF), left bundle branch block and wide QRS duration. Since approximately sixty percent of heart failure patients have a normal QRS duration they do not benefit or respond to the CRT. Cardiac contractility modulation (CCM) releases nonexcitatoy impulses during the absolute refractory period in order to enhance the strength of the left ventricular contraction. The aim of the investigation was to evaluate differences in cardiac index between optimized and nonoptimized CRT and CCM devices versus standard values. Impedance cardiography, a noninvasive method was used to measure cardiac index (CI), a useful parameter which describes the blood volume during one minutes heart pumps related to the body surface. CRT patients indicate an increase of 39.74 percent and CCM patients an improvement of 21.89 percent more cardiac index with an optimized device.

APA, Harvard, Vancouver, ISO, and other styles

20

Mihálcz, Attila, Pál Ábrahám, Attila Kardos, Csaba Földesi, and Tamás Szili-Török. "Cardiac resynchronization therapy for patients with atrial fibrillation." Orvosi Hetilap 152, no. 44 (October 2011): 1757–63. http://dx.doi.org/10.1556/oh.2011.29204.

Full text

Abstract:

Atrial fibrillation and chronic heart failure are two major and even growing cardiovascular conditions that often coexist. Cardiac resynchronization therapy is an important, device-based, non-pharmacological approach in a selected group of chronic heart failure patients that has been shown to improve left ventricular function and to reduce both morbidity and mortality in large randomized trials. The latest European and American guidelines have considered atrial fibrillation patients with heart failure eligible for cardiac resynchronization therapy. This review summarizes current literature concerning the following topics: prognostic relevance of atrial fibrillation in heart failure, effects of cardiac resynchronization therapy in atrial fibrillation, relevance and strategies of rhythm and rate control in this group of patients. Authors explain how atrial fibrillation may interfere with the delivery of adequate cardiac resynchronization therapy, how to reduce the burden of atrial tachyarrhythmias, and finally present a brief overview. Orv. Hetil., 2011, 152, 1757–1763.

APA, Harvard, Vancouver, ISO, and other styles

21

Leahy, Robin A., and Elizabeth E. Davenport. "Home Monitoring for Cardiovascular Implantable Electronic Devices." AACN Advanced Critical Care 26, no. 4 (October 1, 2015): 343–55. http://dx.doi.org/10.4037/nci.0000000000000110.

Full text

Abstract:

Recent technological advances in the management of patients with cardiovascular implantable electronic devices (CIEDs) have expanded clinicians’ ability to remotely monitor patients with CIEDs. Remote monitoring, in addition to periodic in-person device evaluation, provides many advantages to patients and clinicians. Aside from the therapeutic and diagnostic benefits of pacemakers, implantable cardioverter-defibrillators, cardiac resynchronization therapy devices, and implantable loop recorders, improvement in clinical outcomes, clinical efficiencies, and patient experience can be realized with the adoption of remote CIED monitoring. These advantages create significant value to both patients and CIED follow-up centers.

APA, Harvard, Vancouver, ISO, and other styles

22

Leclercq, C., C. Mabo, and J. C. Daubert. "Cardiac resynchronization therapy: which device to implant?" Archives of Cardiovascular Diseases 101, no. 1 (January 2008): 55–60. http://dx.doi.org/10.1016/s1875-2136(08)70256-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

O'DONNELL, D., V. NADURATA, A. HAMER, P. KERTES, and U. MOHAMMED. "Long-Term Variations in Optimal Programming of Cardiac Resynchronization Therapy Devices." Pacing and Clinical Electrophysiology 28, s1 (January 2005): S24—S26. http://dx.doi.org/10.1111/j.1540-8159.2005.00070.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

DUVALL, W. LANE, RIPLE HANSALIA, MELANIE N. WIJETUNGA, SAMANTHA BUCKLEY, and AVI FISCHER. "Advantage of Optimizing V-V Timing in Cardiac Resynchronization Therapy Devices." Pacing and Clinical Electrophysiology 33, no. 10 (May 28, 2010): 1161–68. http://dx.doi.org/10.1111/j.1540-8159.2010.02806.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Parkash, Ratika, Bernard Thibault, Larry Sterns, John Sapp, Andrew Krahn, Mario Talajic, Marilynn Luce, et al. "Sprint Fidelis Lead Fractures in Patients With Cardiac Resynchronization Therapy Devices." Circulation 126, no. 25 (December 18, 2012): 2928–34. http://dx.doi.org/10.1161/circulationaha.112.132100.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Schueler, Melanie, Frederik Voss, Alexander Bauer, Dierk Thomas, Kamilla Kelemen, Hugo A. Katus, and Ruediger Becker. "Atrioventricular delay programming in cardiac resynchronization therapy devices: fixed or adaptive?" Journal of Electrocardiology 45, no. 6 (November 2012): 783–86. http://dx.doi.org/10.1016/j.jelectrocard.2012.05.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Fung, Jeffrey Wing-Hong, and Cheuk-Man Yu. "Implantable cardiac resynchronization therapy devices to monitor heart failure clinical status." Current Heart Failure Reports 4, no. 1 (March 2007): 48–52. http://dx.doi.org/10.1007/s11897-007-0026-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Fung, Jeffrey Wing-Hong, and Cheuk-Man Yu. "Leveraging cardiac resynchronization therapy devices to monitor patients with heart failure." Current Heart Failure Reports 5, no. 1 (March 2008): 44–50. http://dx.doi.org/10.1007/s11897-008-0008-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Adamczyk, Karolina, and Ewa Jędrzejczyk-Patej. "Local complications in patients with cardiac implantable devices." In a good rythm 1, no. 50 (April 15, 2019): 14–18. http://dx.doi.org/10.5604/01.3001.0013.1684.

Full text

Abstract:

Cardiac implantable electronic devices (CIEDs) such as pacemakers (PMs), implantable cardioverter-defibrillators (ICDs), both with or without cardiac resynchronization therapy (CRT), became one of the fundamental therapies in present-day electrocardiology. The CIED patients population is increasing year by year due to a growing number of CIED implantations annually and a life prolongation among patients with CIEDs through better pharmacology combined with the proper electrotherapy and patient care. Invasive procedures related to CIED such as an implantation, a replacement or an up-grade of any kind electrotherapy device involves the risk of complications. Pocket hematoma or infection, which are local complications, should be recognized rapidly and treat properly in order to avoid more threatening systemic complications.

APA, Harvard, Vancouver, ISO, and other styles

30

Zimpfer, D., D. Wiedemann, and A. Neissner. "Implantable devices: a bridge to heart transplantation." Russian Journal of Transplantology and Artificial Organs 20, no. 4 (January 31, 2019): 134–41. http://dx.doi.org/10.15825/1995-1191-2018-4-134-141.

Full text

Abstract:

Terminal stage heart failure represents a substantial worldwide problem for the healthcare system. Despite significant improvements (medical heart failure treatment, implantable cardioverters, cardiac resynchronization devices), long-term survival and quality of life of these patients remain poor. Heart transplantation has been an effective therapy for terminal heart failure, but it remains limited by an increasing shortage of available donor organs along with strict criteria defining acceptable recipients.

APA, Harvard, Vancouver, ISO, and other styles

31

Bhatia, Meena, Payam Safavi-Naeini, Mehdi Razavi, Charles D. Collard, Daniel A. Tolpin, and James M. Anton. "Anesthetic Management of Laser Lead Extraction for Cardiovascular Implantable Electronic Devices." Seminars in Cardiothoracic and Vascular Anesthesia 21, no. 4 (September 21, 2017): 302–11. http://dx.doi.org/10.1177/1089253217728581.

Full text

Abstract:

Cardiovascular implantable electronic devices (CIEDs) play a significant role in the modern management of cardiovascular disease. CIEDs include implantable pacemakers (PMs), implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices. These devices improve the quality of life of their recipients and help reduce the incidence of sudden cardiac death. Traditionally, CIEDs have been reliant on the use of transvenous endocardial leads to directly connect with the heart. Over time, these endovascular leads may become endothelialized rendering removal extremely difficult. As the indications for CIEDs expands and with the continuing evolution of these devices, the number of patients requiring explantation for device recall, malfunction, and infection continues to increase. In this manuscript, we review the most common CIEDs, the indications and process of lead removal/device explantation, potential complications associated with the procedure and the anesthetic management of these patients.

APA, Harvard, Vancouver, ISO, and other styles

32

Pescariu, Silvius-Alexandru, Raluca Şoşdean, Bogdan Enache, Răzvan I. Macarie, Mariana Tudoran, Cristina Tudoran, Cristian Mornoş, Adina Ionac, and Sorin Pescariu. "Single-Pass VDD Pacing Lead for Cardiac Resynchronization Therapy: A Reliable Alternative." Micromachines 12, no. 8 (August 18, 2021): 978. http://dx.doi.org/10.3390/mi12080978.

Full text

Abstract:

(1) Background: Cardiac resynchronization therapy (CRT) systems can be simplified by excluding the atrial lead and using a Ventricular-Dual-Dual (VDD) pacing lead. Possible disadvantages might include atrial undersensing and Ventricular-Ventricular-Inhibition (VVI) pacing. Because literature data concerning these systems are scarce, we analyzed their benefits and technical safety. (2) Methods: this retrospective study compared 50 patients implanted with VDD–CRT systems (group A), mainly because of unfavorable venous anatomy concerning the complication rate, with 103 subjects with Dual-Dual-Dual (DDD)–CRT systems (group B) implanted during 2000–2016 and 49 (group C) during 2016–2020. To analyze the functional parameters of the devices, we selected subgroups of 27 patients (subgroup A) and 47 (subgroup B) patients with VDD–CRT in 2000–2016, and 36 subjects (subgroup C) with DDD–CRT implanted were selected in 2017–2020. (3) Results: There was a trend of a lower complication rate with VDD–CRT systems, especially concerning infections during 2000–2016 (p = 0.0048), but similar results were obtained after rigorous selection of patients and employment of an upgraded design of devices/leads. With a proper device programing, CRT pacing had similar results, atrial undersensing being minimal (p = 0.65). For VDD-systems, VVI pacing was recorded only 1.7 ± 2.24% of the time. (4) Conclusions: In patients with a less favorable venous anatomy, VDD–CRT systems may represent a safe alternative regarding complications rates and functional parameters.

APA, Harvard, Vancouver, ISO, and other styles

33

Katbeh, Asim, Guy Van Camp, Emanuele Barbato, Maurizio Galderisi, Bruno Trimarco, Jozef Bartunek, Marc Vanderheyden, and Martin Penicka. "Cardiac Resynchronization Therapy Optimization: A Comprehensive Approach." Cardiology 142, no. 2 (2019): 116–28. http://dx.doi.org/10.1159/000499192.

Full text

Abstract:

Since the first report on biventricular pacing in 1994, cardiac resynchronization therapy (CRT) has become standard for patients with advanced heart failure (HF) and ventricular conduction delay. CRT improves myocardial function by resynchronizing myocardial contraction, which results in reverse left ventricular remodeling and improves symptoms and clinical outcomes. Despite the accelerated development of CRT device technology and its increased application in treating HF patients, almost one-third of these patients do not respond to the therapy or gain any clinical benefit from device implantation. Over the last decade, multiple cardiac imaging modalities have provided a deeper understanding of myocardial pathophysiology, thereby improving HF treatment management. However, the optimal strategy for improving the CRT response remains debatable. This article provides an updated overview of the electropathophysiology of myocardial dysfunction in ventricular conduction delay and the diagnostic approaches involving the use of multiple modalities.

APA, Harvard, Vancouver, ISO, and other styles

34

Paton, Maria F., Maurizio Landolina, Jean-Renaud Billuart, Duncan Field, Jonathan Sibley, and Klaus Witte. "Projected longevities of cardiac implantable defibrillators: a retrospective analysis over the period 2007–17 and the impact of technological factors in determining longevity." EP Europace 22, no. 1 (August 13, 2019): 149–55. http://dx.doi.org/10.1093/europace/euz222.

Full text

Abstract:

Abstract Aims Implanters of cardiac implantable electronic devices cannot easily choose devices by longevity as usually current models only have projected longevity data since those with known performance are obsolete. This study examines how projected device longevities are derived, the influencing factors, and their roles in guiding model choice. Methods and results Ninety-eight implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy-defibrillator (CRT-D) models released in Europe in 2007–17 were analysed for reported battery capacities, projected longevities for standardized settings stipulated by the French Haute Autorité de Santé (HAS) and manufacturer-chosen settings. Battery capacities and HAS projected longevities increased during the study period. Based on current drain estimation, therapy functions consumed only a small portion (2–7%) of the battery energy for single- and dual-chamber ICDs, but up to 50% (from biventricular pacing) for CRT-Ds. Large differences exist between manufacturers and models both in terms of battery capacity and energy consumption. Conclusion Battery capacity is not the sole driver of longevity for electronic implantable cardiac devices and, particularly for ICDs, the core function consume a large part of the battery energy even in the absence of therapy. Providing standardized current drain consumption in addition to battery capacity may provide more meaningful longevity information among implantable electronic cardiac devices.

APA, Harvard, Vancouver, ISO, and other styles

35

Mihajlovic, Marina, Dora Fabijanovic, Martina Lovric Bencic, and Ana Ljubas. "Improved quality of life in patients with implanted cardiac resynchronization therapy devices." Cardiologia Croatica 9, no. 5-6 (May 22, 2014): 214. http://dx.doi.org/10.15836/ccar.2014.214.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Bonomini, María P., Daniel F. Ortega, Emilio Logarzo, Nicolás Mangani, and Analía Paolucci. "Usefulness of ventricular sense response in last-generation cardiac resynchronization therapy devices." Journal of Electrocardiology 71 (March 2022): 47–52. http://dx.doi.org/10.1016/j.jelectrocard.2022.01.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

LEVIN, VADIM, MEHDI RAZAVI, ROBERT COLL, JAMES A. COLES Jr, and ALEKSANDRE SAMBELASHVILI. "Interatrial Conduction Correlates with Optimal Atrioventricular Timing in Cardiac Resynchronization Therapy Devices." Pacing and Clinical Electrophysiology 34, no. 4 (January 5, 2011): 443–49. http://dx.doi.org/10.1111/j.1540-8159.2010.02988.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Romeyer-Bouchard, C., A. Da Costa, V. Dauphinot, M. Messier, L. Bisch, B. Samuel, P. Lafond, P. Ricci, and K. Isaaz. "Prevalence and risk factors related to infections of cardiac resynchronization therapy devices." European Heart Journal 31, no. 2 (October 28, 2009): 203–10. http://dx.doi.org/10.1093/eurheartj/ehp421.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Behaghel, Albin, Anne Brunet-Bernard, Emmanuel Oger, Raphaël Martins, Erwan Donal, Maxime Fournet, Damien Feneon, Christophe Leclercq, Philippe Mabo, and Claude Daubert. "Electrocardiographic correlates of mechanical dyssynchrony in recipients of cardiac resynchronization therapy devices." Archives of Cardiovascular Diseases 108, no. 12 (December 2015): 617–25. http://dx.doi.org/10.1016/j.acvd.2015.06.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

van Rees, Johannes B., Mihály K. de Bie, Joep Thijssen, C. Jan Willem Borleffs, Martin J. Schalij, and Lieselot van Erven. "Implantation-Related Complications of Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Devices." Journal of the American College of Cardiology 58, no. 10 (August 2011): 995–1000. http://dx.doi.org/10.1016/j.jacc.2011.06.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Mabo, P., and G. Carrault. "Are Electronic Cardiac Devices Still Evolving?" Yearbook of Medical Informatics 23, no. 01 (August 2014): 128–34. http://dx.doi.org/10.15265/iy-2014-0021.

Full text

Abstract:

Summary Objectives: The goal of this paper is to review some important issues occurring during the past year in Implantable devices. Methods: First cardiac implantable device was proposed to maintain an adequate heart rate, either because the heart’s natural pacemaker is not fast enough, or there is a block in the heart’s electrical conduction system. During the last forty years, pacemakers have evolved considerably and become programmable and allow to configure specific patient optimum pacing modes. Various technological aspects (electrodes, connectors, algorithms diagnosis, therapies, ...) have been progressed and cardiac implants address several clinical applications: management of arrhythmias, cardioversion / defibrillation and cardiac resynchronization therapy. Results: Observed progress was the miniaturization of device, increased longevity, coupled with efficient pacing functions, multisite pacing modes, leadless pacing and also a better recognition of supraventricular or ventricular tachycardia’s in order to deliver appropriate therapy. Subcutaneous implant, new modes of stimulation (leadless implant or ultrasound lead), quadripolar lead and new sensor or new algorithm for the hemodynamic management are introduced and briefly described. Each times, the main result occurring during the two past years are underlined and repositioned from the history, remaining limitations are also addressed. Conclusion: Some important technological improvements were described. Nevertheless, news trends for the future are also considered in a specific session such as the remote follow-up of the patient or the treatment of heart failure by neuromodulation.

APA, Harvard, Vancouver, ISO, and other styles

42

Świerżyńska, Ewa, and Maciej Sterliński. "Magnetic resonance in patients with implanted electronic cardiac devices in light of the 2021 ESC cardiac pacing and cardiac resynchronization therapy guidelines." In a good rythm 3, no. 60 (December 30, 2021): 8–12. http://dx.doi.org/10.5604/01.3001.0015.7294.

Full text

Abstract:

For over a decade, implantable electrotherapy devices have been available which allow — under certain conditions — diagnostic magnetic resonance imaging (MRI) tests to be performed. Detailed recommendations for the performance of these tests have been published in the latest guidelines by the European Society of Cardiology (ESC). The latest guidelines, compared to the 2013 recommendations, changed the recommendation class for MRI examinations. They strongly emphasised that the presence of a typical pacing system, cardioverter-defibrillator or resynchronization system, does not constitute a contraindication to MRI diagnostics. The guidelines also indicate that under certain conditions, such tests are safe and should be performed. This article presents detailed recommendations of the qualifications required for an MRI and the programming devices recommended by the ESC.

APA, Harvard, Vancouver, ISO, and other styles

43

ROM, RAMI, JACOB EREL, MICHAEL GLIKSON, KOBI ROSENBLUM, RAN GINOSAR, and DAVID L. HAYES. "Adaptive Cardiac Resynchronization Therapy Device: A Simulation Report." Pacing and Clinical Electrophysiology 28, no. 11 (November 2005): 1168–73. http://dx.doi.org/10.1111/j.1540-8159.2005.40007.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

BURRI, HARAN, HENRI SUNTHORN, DIPEN SHAH, and RENÉ LERCH. "Optimization of Device Programming for Cardiac Resynchronization Therapy." Pacing and Clinical Electrophysiology 29, no. 12 (December 2006): 1416–25. http://dx.doi.org/10.1111/j.1540-8159.2006.00557.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Yamada, Takashi, Kenji Ando, Yoshimitsu Soga, Masahiko Goya, Hitoshi Yasumoto, and Masakiyo Nobuyoshi. "Cardiac Resynchronization Therapy After Device Implantation for Bradycardia." Journal of Cardiac Failure 13, no. 6 (August 2007): S44. http://dx.doi.org/10.1016/j.cardfail.2007.06.202.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Davis, Margot K., and Sean A. Virani. "Cardiac Resynchronization Therapy in the Cardiorenal Syndrome." International Journal of Nephrology 2011 (2011): 1–6. http://dx.doi.org/10.4061/2011/168461.

Full text

Abstract:

The cardiorenal syndrome (CRS) is a complex clinical syndrome in which dysfunction of either the heart or the kidneys affects the functioning of the other organ system. Many therapies used in heart failure have further detrimental effects on renal function. Cardiac resynchronization therapy (CRT) is a relatively new form of device therapy that reduces morbidity and mortality in patients with heart failure. This review will discuss the effects of CRT on renal function in patients with CRS, the impact of baseline renal function on response to CRT, and potential risks associated with CRT in this unique population.

APA, Harvard, Vancouver, ISO, and other styles

47

Sherry, Daisy, Bradley P. Knight, Cash Casey, Janet Larson, Eileen D. Hacker, Lauretta T. Quinn, Edward Wang, and Eileen G. Collins. "A Pilot Study Evaluating Daily Physical Activity Before and After Cardiac Resynchronization Therapy." Biological Research For Nursing 16, no. 1 (March 28, 2013): 31–37. http://dx.doi.org/10.1177/1099800413481619.

Full text

Abstract:

Benefits of daily physical activity are well known, but there are limited data to describe physical activity in heart failure patients who receive cardiac resynchronization therapy devices. The purpose of this pilot study was to evaluate changes in physical activity (PA) levels before and 3 months after Cardiac Resynchronization Therapy (CRT) and determine relationships of PA to physical function and comorbidities, as well as describe changes in heart failure symptoms. This was a prospective pre-/post- design that included a convenience sample of 21 subjects using self- report questionnaires and 6-minute walk test (6MWT). In this sample, there was a 2.6 hour increase in high level PA (p = 0.024). 6MW distance improved 27% (p < .0001). Subjects experienced a 25% reduction in dyspnea (p = 0.015). Knowledge gained from this study adds to the understanding of the patient response to CRT. Further study is recommended to generalize findings and explore whether an intervention (cardiac rehabilitation) is indicated.

APA, Harvard, Vancouver, ISO, and other styles

48

Hernandez-Madrid, Antonio, Domenico Facchin, Ruth Klepfer, Subham Ghosh, Roberto Matía, Javier Moreno, and Alessandro Locatelli. "99-06: Device Pacing Diagnostics Overestimate Effective Cardiac Resynchronization Therapy Pacing Results of the hOLter for Efficacy analysis of Cardiac Resynchronization Therapy Study (OLÉ Cardiac Resynchronization Therapy study)." EP Europace 18, suppl_1 (June 2016): i176. http://dx.doi.org/10.1093/europace/18.suppl_1.i176a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Miyazaki, Aya. "Cardiac Implantable Electrical Devices in Pediatric Cardiology: Pacemaker, Implantable Cardioverter Defibrillator, and Cardiac Resynchronization Therapy." Pediatric Cardiology and Cardiac Surgery 34, no. 4 (December 20, 2018): 172–81. http://dx.doi.org/10.9794/jspccs.34.172.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Kluk, Maciej Krzysztof, and Wojciech Gutkowski. "Implementation of an antibacterial envelope during de novo implantation of ICD system in secondary SCD prevention in a patient on immunosuppressive treatment." In a good rythm 3, no. 64 (December 5, 2022): 17–20. http://dx.doi.org/10.5604/01.3001.0016.1827.

Full text

Abstract:

Implantation of cardioverter-defibrillator system is necessary and it needs to be performed as soon as possible in patients with secondary sudden cardiac death prevention including resynchronization therapy indications. Patients on active immunosuppressive treatment are at the highest risk of infective complications of every kind of surgical intervention. In the case of cardiac implantable devices implementation of an antibacterial envelope could be a relevant factor in infective risk prevention.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!